OBJECTIVE: To report oncologic outcomes and complications after robotic-assisted radical cystectomy (RARC). MATERIALS AND METHODS: From March 2004 to August 2011, 175 consecutive patients underwent RARC with extracorporeal urinary diversion at our institution by a single surgeon. The study design was prospective. Perioperative parameters and postoperative complications were prospectively collected using the modified Clavien system. Recurrence-free survival and cancer-specific survival curves were generated using the Kaplan-Meier method. RESULTS: A total of 145 men and 30 women with a median age of 73 years and a median body mass index of 27 kg/m(2) underwent RARC. Four patients (2.3%) required conversion to open surgery because of difficulty to progress. One hundred nine patients (62%) underwent a transcutaneous ileal conduit, 40 patients (23%) an orthotopic neobladder, and 26 (15%) a continent cutaneous conduit. The median operating time was 360 minutes (interquartile range [IQR]: 300-420). The median estimated blood loss was 400 mL (IQR: 250-612), with a transfusion rate of 17.0%. The median postoperative length of stay was 7.0 days (IQR: 5.2-10). Early (<30 days) and late surgery-related complications (30-90 days) occurred in 74 (42%) and 59 (34%) patients, respectively. The perioperative mortality rate was 2.8%. The positive soft tissue surgical margins rate was 5%. The median number of lymph nodes removed was 19 (IQR: 12-28). The median follow-up was 37 months (IQR: 21.5-53.5). Actuarial recurrence-free survival and cancer-specific survival at 2, 3, and 5 years after RARC were 67%, 63%, 63% and 73%, 68%, 66%, respectively. CONCLUSION: RARC achieved mid-term oncologic efficacy. Moreover, the complication rates were comparable with open radical cystectomy series.
OBJECTIVE: To report oncologic outcomes and complications after robotic-assisted radical cystectomy (RARC). MATERIALS AND METHODS: From March 2004 to August 2011, 175 consecutive patients underwent RARC with extracorporeal urinary diversion at our institution by a single surgeon. The study design was prospective. Perioperative parameters and postoperative complications were prospectively collected using the modified Clavien system. Recurrence-free survival and cancer-specific survival curves were generated using the Kaplan-Meier method. RESULTS: A total of 145 men and 30 women with a median age of 73 years and a median body mass index of 27 kg/m(2) underwent RARC. Four patients (2.3%) required conversion to open surgery because of difficulty to progress. One hundred nine patients (62%) underwent a transcutaneous ileal conduit, 40 patients (23%) an orthotopic neobladder, and 26 (15%) a continent cutaneous conduit. The median operating time was 360 minutes (interquartile range [IQR]: 300-420). The median estimated blood loss was 400 mL (IQR: 250-612), with a transfusion rate of 17.0%. The median postoperative length of stay was 7.0 days (IQR: 5.2-10). Early (<30 days) and late surgery-related complications (30-90 days) occurred in 74 (42%) and 59 (34%) patients, respectively. The perioperative mortality rate was 2.8%. The positive soft tissue surgical margins rate was 5%. The median number of lymph nodes removed was 19 (IQR: 12-28). The median follow-up was 37 months (IQR: 21.5-53.5). Actuarial recurrence-free survival and cancer-specific survival at 2, 3, and 5 years after RARC were 67%, 63%, 63% and 73%, 68%, 66%, respectively. CONCLUSION: RARC achieved mid-term oncologic efficacy. Moreover, the complication rates were comparable with open radical cystectomy series.
Authors: Karthik Tanneru; Seyed Behzad Jazayeri; Jatinder Kumar; Muhammad Umar Alam; Daniel Norez; Sabine Nguyen; Soroush Bazargani; Hariharan Palayapalayam Ganapathi; Mark Bandyk; Robert Marino; Shahriar Koochekpour; Shiva Gautam; K C Balaji; Joseph Costa Journal: J Robot Surg Date: 2020-11-22
Authors: Bernard H Bochner; Guido Dalbagni; Karim H Marzouk; Daniel D Sjoberg; Justin Lee; Sheri M Donat; Jonathan A Coleman; Andrew Vickers; Harry W Herr; Vincent P Laudone Journal: Eur Urol Date: 2018-05-18 Impact factor: 20.096
Authors: Daniel P Nguyen; Bashir Al Hussein Al Awamlh; Xian Wu; Padraic O'Malley; Igor M Inoyatov; Abimbola Ayangbesan; Bishoy M Faltas; Paul J Christos; Douglas S Scherr Journal: Eur Urol Date: 2015-02-20 Impact factor: 20.096
Authors: Ji Sung Shim; Tae Gyun Kwon; Koon Ho Rha; Young Goo Lee; Ji Youl Lee; Byong Chang Jeong; Jae Yoon Kim; Jong Hyun Pyun; Sung Gu Kang; Seok Ho Kang Journal: J Korean Med Sci Date: 2017-10 Impact factor: 2.153
Authors: Sophia Liff Maibom; Ulla Nordström Joensen; Alicia Martin Poulsen; Henrik Kehlet; Klaus Brasso; Martin Andreas Røder Journal: BMJ Open Date: 2021-04-14 Impact factor: 2.692